Prelude Capital Management, LLC Cti Biopharma Corp Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 14, 2018
SELL
$2.47 - $3.34 $2,223 - $3,006
-900 Closed
0 $0
Q3 2017

Nov 14, 2017
BUY
$3.12 - $3.65 $2,808 - $3,285
900
900 $3,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email